ARCA biopharma to Present at Seventh Annual BIO Investor Forum
23 Octobre 2008 - 1:30PM
PR Newswire (US)
Webcast Presentation Scheduled for Wednesday, October 29, 2008 at
3:15 p.m. PDT BROOMFIELD, Colo. and SAN CARLOS, Calif., Oct. 23
/PRNewswire-FirstCall/ -- ARCA biopharma, Inc., a biopharmaceutical
company developing genetically-targeted therapies for heart failure
and other cardiovascular diseases, and Nuvelo, Inc. (NASDAQ:NUVO)
today announced that Michael Bristow, M.D., Ph.D., ARCA's chairman
and chief science and medical officer, will present at the Seventh
Annual BIO Investor Forum on Wednesday, October 29, 2008, at 3:15
p.m. PDT in San Francisco. ARCA biopharma and Nuvelo, Inc.
announced on September 25, 2008 that they have entered into a
definitive merger agreement, expected to create a
cardiovascular-focused, late-stage biotechnology company. The
presentation will discuss the assets of both companies, including
ARCA's lead product Gencaro(TM) (bucindolol hydrochloride) a
near-term commercial opportunity, as well as Nuvelo's mid-stage
pipeline asset, novel short-acting anticoagulant NU172, to drive
long-term growth. ARCA recently announced that the FDA has accepted
for filing a New Drug Application for Gencaro. The presentation
will also discuss the structure and strategic plan of the combined
company, pending the closing of the merger. A live audio webcast of
the presentation will be available online via the ARCA biopharma
website at http://www.arcabiopharma.com/ or the Investor Relations
portion of Nuvelo's website at http://www.nuvelo.com/. In addition
to the corporate presentation, Dr. Bristow will also participate in
a panel discussion titled "Congestive Heart Failure: New
Therapeutics to Improve CHF Outcomes," which is taking place on
Thursday, October 30, at 9:30 a.m. PDT. The panel will feature
leading clinical investigators and physicians in the field of
congestive heart failure and seek to address key issues facing
clinical-stage biopharmaceuticals targeting treatment of the
disease. About ARCA biopharma ARCA biopharma, Inc. is a privately
held company focused on developing and commercializing genetically
targeted therapies for heart failure and other cardiovascular
diseases. The Company's lead product candidate, Gencaro(TM)
(bucindolol hydrochloride), is an investigational pharmacologically
unique beta-blocker and mild vasodilator being developed for heart
failure and other indications. ARCA has identified common genetic
variations that predict individual patient response to Gencaro. The
NDA for Gencaro, including the proposed brand name, is under review
by FDA. The companion genetic test for Gencaro is in development by
ARCA's partner, Laboratory Corporation of America. For more
information please visit http://www.arcabiopharma.com/. About
Nuvelo Nuvelo, Inc. is dedicated to improving the lives of patients
through the discovery, development and commercialization of novel
drugs for acute cardiovascular disease, cancer and other
debilitating medical conditions. Nuvelo's development pipeline
includes NU172, a direct thrombin inhibitor which has completed
Phase 1 development for use as a potential short-acting
anticoagulant during medical or surgical procedures; and NU206, a
Wnt pathway modulator in Phase 1 development for the potential
treatment of chemotherapy/radiation therapy-induced mucositis and
inflammatory bowel disease. In addition, Nuvelo is pursuing
research programs in leukemia and lymphoma therapeutic antibodies
and Wnt signaling pathway therapeutics to further expand its
pipeline and create additional partnering and licensing
opportunities. Information about Nuvelo is available at its website
at http://www.nuvelo.com/ or by phoning 650-517-8000.
Forward-looking statements This press release contains
"forward-looking statements" which include, without limitation,
statements regarding the completion of the proposed merger
transaction between Nuvelo, ARCA and Dawn Acquisition Sub, Inc.,
the transaction's anticipated benefits, timing, progress and
anticipated completion of the combined company's clinical stage and
research programs, which statements are hereby identified as
"forward-looking statements" for purposes of the safe harbor
provided by the Private Securities Litigation Reform Act of 1995.
Such statements are based on the companies' managements' current
expectations and involve risks and uncertainties. Actual results
and performance could differ materially from those projected in the
forward-looking statements as a result of many factors, including,
without limitation, failure of Nuvelo or ARCA's stockholders to
approve the merger, the ability to complete the transaction
contemplated by this communication in a timely fashion, the risk
that Nuvelo's and ARCA's business operations will not be integrated
successfully; the combined company's inability to further identify,
develop and achieve commercial success for products and
technologies; the risk that the combined company's financial
resources will be insufficient to meet the combined company's
business objectives; uncertainties relating to drug discovery and
the regulatory approval process; clinical development processes;
enrollment rates for patients in the companies' clinical trials;
changes in relationships with strategic partners and dependence
upon strategic partners for the performance of critical activities
under collaborative agreements; and the impact of competitive
products and technological changes. These and other factors are
identified and described in more detail in Nuvelo's filings with
the SEC, including without limitation Nuvelo's quarterly report on
Form 10-Q for the quarter ended June 30, 2008 and subsequent
filings. We disclaim any intent or obligation to update these
forward-looking statements. Additional Information and Where to
Find It Nuvelo intends to file a registration statement on Form
S-4, and a related proxy statement/prospectus/consent solicitation,
in connection with the merger. Investors and security holders are
urged to read the registration statement on Form S-4 and the
related proxy statement/prospectus/consent solicitation when they
become available because they will contain important information
about the merger transaction. Investors and security holders may
obtain free copies of these documents (when they are available) and
other documents filed with the SEC at the SEC's website at
http://www.sec.gov/. In addition, investors and security holders
may obtain free copies of the documents filed with the SEC by
contacting Nuvelo Investor Relations at the email address: or by
phone at 650-517-8000. In addition to the registration statement
and related proxy statement/prospectus/consent solicitation, Nuvelo
files annual, quarterly and special reports, proxy statements and
other information with the SEC. You may read and copy any reports,
statements or other information filed by Nuvelo, Inc. at the SEC
public reference room at 100 F Street, N.E., Washington, D.C.
20549. Please call the SEC at 1-800-SEC-0330 for more information.
Please call the SEC at 1-800-SEC-0330 for further information on
the public reference room. Nuvelo, Inc.'s filings with the SEC are
also available to the public from commercial document-retrieval
services and at SEC's website at http://www.sec.gov/, and from
Investor Relations at Nuvelo as described above. This communication
shall not constitute an offer to sell or the solicitation of an
offer to sell or the solicitation of an offer to buy any
securities, nor shall there be any sale of securities in any
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. No offering of securities
shall be made except by means of a prospectus meeting the
requirements of Section 10 of the Securities Act of 1933, as
amended. Nuvelo, ARCA and their respective directors and executive
officers may be deemed to be participants in the solicitation of
proxies from the stockholders of Nuvelo in connection with the
merger transaction. Information regarding the special interests of
these directors and executive officers in the merger transaction
will be included in the proxy statement/prospectus of described
above. Additional information regarding the directors and executive
officers of Nuvelo is also included in Nuvelo's proxy statement for
its 2008 Annual Meeting of Stockholders which was filed with the
SEC on April 23, 2008 and its Annual Report on Form 10-K for the
year ended December 31, 2007, which was filed with the SEC on March
12, 2008. These documents are available as described above.
DATASOURCE: ARCA biopharma, Inc. and Nuvelo, Inc. CONTACT: Greg Gin
of Invigorate Communications, Inc., +1-908-376-7737, ; or Danielle
Bertrand of WeissComm Partners, Inc., +1-415-946-1056, , for ARCA
biopharma, Inc. and Nuvelo, Inc. Web site:
http://www.arcabiopharma.com/ http://www.nuvelo.com/
Copyright
Holdco Nuvo Group DG (NASDAQ:NUVO)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Holdco Nuvo Group DG (NASDAQ:NUVO)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024